Eptinezumab

Not Applicable

04/06/2024 Calcitonin gene-related peptide (CGRP) monoclonal antibodies for prophylaxis of migraine

The Ministry of Health’s Drug Advisory Committee has recommended:

• Galcanezumab 120 mg/mL solution for injection in pre-filled pen for prophylaxis of migraine in adults who have at least four migraine days a month prior to commencement of treatment with galcanezumab. Patients must have experienced an inadequate response, intolerance, or a contraindication to at least three migraine prophylactic medications. Treatment with galcanezumab should be stopped after 12 weeks if:
  a) in episodic migraine, the number of migraine days per month does not reduce by at least 50% compared with baseline;
  b) in chronic migraine, the number of migraine days per month does not reduce by at least 30% compared with baseline.

Funding status

[R] Galcanezumab 120 mg/mL solution for injection in pre-filled pen is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2024.

[NR] MAF assistance does not apply to galcanezumab 100 mg/mL solution for injection in pre-filled syringe, or any formulations or strengths of eptinezumab, erenumab or fremanezumab.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.